Mass Spectrometry Quantification of Personalized Biomarkers for Multiple Myeloma
Moffitt Cancer Center/University of South Florida
Multiple Myeloma, an incurable disease with poor patient outcomes, is characterized by clonal expansion of the plasma cells in the bone marrow, which secrete a monoclonal immunoglobulin. This study utilizes a proteogenomics approach to develop individualized, peptide-based mass spectrometry assays to quantify each patient’s disease-specific biomarker. Personalized LC-MRM assays developed for variable region peptides using de novo RNA sequencing have shown a substantial increase in sensitivity compared to clinical methods. The increase in sensitivity improves minimal residual disease detection, which could improve patient outcomes.
Presented at MSACL 2016 US